Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aquamin is a natural multi-mineral product derived from the calcified red seaweed *Lithothamnion calcareum*. It is rich in calcium and magnesium, along with 72 additional trace minerals. Research led by James Varani at the University of Michigan has demonstrated that Aquamin enhances gastrointestinal barrier function by upregulating the expression of tight junction proteins, such as occludin and claudin-1, and by promoting the differentiation of intestinal epithelial cells. This mechanism is thought to reduce gastrointestinal permeability, a key factor in inflammatory bowel diseases and functional GI disorders. Aquamin is currently being evaluated in Phase 2 clinical trials for its efficacy in reducing gut permeability and inflammation in patients with ulcerative colitis and irritable bowel syndrome with diarrhea (IBS-D).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aquamin.